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1. Introduction
In most of gastrointestinal disorders, endoscopy has a major diagnostic and therapeutic role,
but though its clinical efficacy and safety have been established, it is not that well known
when performing it in pregnant patients, due to the potential harm of the foetus like hypo‐
xia, teratogenesis, trauma, placental abruption or induction of premature labor.
Endoscopy is generally considered to be a low risk procedure, the most frequently being
performed at the patient`s request in ambulatory but also in hospitals [1]. Nevertheless, the
safety and effectiveness of gastrointestinal endoscopy in particular circumstances at the
pregnant woman has not been yet well studied. During the pregnancy the risks for the fetus
and mother are various and the magnitude of this risk is different, according to the trimes‐
ter. Taking into consideration the difficulties in the performance of those studies to pregnant
women these risks have not been enough evaluated.
The main concern is the fetal safety and endoscopic medication and use of sedative and an‐
algesics represent a significant risk if they are not chosen properly. It is strongly indicated
the presence of an anesthesiologist and an obstetrician, in selected cases when a pregnancy-
related complication is most probable. Before the procedure, the pregnant patient should be
well evaluated by the gastroenterologist, anesthesiologist and obstetrician and should be in‐
formed about the potential risks of sedation and analgesia.
Because  of  the  fact  that  there  are  potential  risks  for  the  fetus  and  for  the  pregnant
woman, the indications of endoscopy to pregnant women limit to superior gastrointesti‐
nal  hemorrhages,  dysphagia,  uncontrolled  nausea/vomits,  rectal  bleeding,  diarrhea,  bili‐
ary  lithiasis  or  biliary  pancreatitis  [2].  For  that  matter,  endoscopy for  pregnant  women
is  considered to be a  very rare procedure;  in  USA only 19000 pregnant  women do this
type of annual investigation [3].
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It is being performed during the pregnancy only when there are no other ways of diagnosis
or therapy less invasive, the indications for the procedure are clear and as much as possible
the gastroscopy should be postponed until third trimester.
The safety of gastrointestinal endoscopy during the pregnancy was evaluated by Cappell et
al [4] who performed esophago-gastro-duodenoscopies on a lot of 83 pregnant women and
concluded on the fact that the procedure is safe and does not induce birth or congenital mal‐
formations. The same authors investigated the safety of sigmoidscopy to 46 patients and es‐
tablished the safety of the procedure to the pregnant women who had small gastrointestinal
bleeding and avoided to induce early labor and the appearance of congenital malformations.
Nevertheless, as a result of data which are rather limited and incomplete in what concerns
the safety of the procedure, fetal risk to endoscopy in the pregnancy has not been complete‐
ly excluded. In that effect, in Qureshi`s work et al. which has been approved by the Ameri‐
can Society of Endoscopic Gastrointestinal Endoscopy (ASGE, 2005) there had been
distinguished the principles that the doctor must comply with when he decides to make en‐
doscopies to a pregnant woman [5].
2. Physiological modifications in the pregnancy and the endoscopy
Pregnant women are susceptible to gastrointestinal reflux disease, biliary tract complica‐
tions and gastrointestinal bleeding, thus needing to be performed upper endoscopy, ERCP
or colonoscopy. For example, only in the United States, upper endoscopy was necessary in
over 12,000 pregnant patients per year and colonoscopy or sigmoidoscopy in more than
6000 pregnant patients per year. ERCP is also needed, as cholelithiasis has a 12% incidence
in pregnant patients. Latest studies suggest that, if having good indication (upper gastroin‐
testinal bleeding, refractory nausea or vomiting), upper endoscopy is relatively safe in preg‐
nant patients.
Increase in size of pregnant uterus determines the lift of stomach along with the modifica‐
tion of intra abdominal segment of esophagus that gets into the thorax. As a result it is being
reduced the tonus of the inferior esophagian sphincter and increases intragastric pressure
which predisposes to gastroesophageal reflux. Even if gastric volume and acidity of gastric
juice does not modify during the pregnancy, the pregnant women show a regurgitating risk
through the decrease of pressure barrier of inferior eshophageal sphincter. This risk justifies
the pharmacological methods of reduction of gastric secretion. 50-80% from the pregnant
women show “retrosternal burning-pyrosis” which is the clinical correspondent of gastro-
esophageal reflux. On those grounds, the pregnant women are considered as having a full
stomach [6].
During the last months of pregnancy, the pregnant uterus modifies anatomic relations be‐
tween abdominal and pelvic organs. These modifications can extend the time of perform‐
ance of the procedure, they can increase the quantity of anaesthesic medicines that are being
administered and the air quantity inoculated in order to facilitate the intraluminal visualiza‐
tion. In order to diminish the compression of vena cava by the pregnant uterus there should
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be adopted the lying down position of the pregnant woman, position that was used in a nor‐
mal way for colonoscopy. For those grounds, the endoscopist must be accustomed with en‐
doscopic procedures to pregnant women and fully evaluate anatomic and pathological
modifications of superior and interior gastrointestinal tract.
Biliary oversaturation and biliary hypomotility are as well frequently seen as physiological
modifications that appear during the pregnancy. Unfortunately, this can lead to the forma‐
tion of biliary sludge and biliary calculi, which at their turn can widen biliary colics, chole‐
cystitis and even pancreatitis.
Airway mucosa is edematiated during the pregnancy, showing a reduction of airways.
Moreover, there is a compensatory increase of ventilation on each minute in order to answer
to demands of maternal and fetal oxygen. Nevertheless, pulmonary capacity is reduced as a
result of ascension of the diaphragm.
As well, during the pregnancy there appear hemodynamic modifications. Cardiac frequency
increases from 90 to 100 beats a minute. Systolic arterial pressure can increase. Pregnant
women cannot often tolerate the supine position, especially after 30 pregnancy weeks, given
reduced arterial pressure because of big weight of the uterus.
3. Endoscopy indications during pregnancy
Endoscopy should be performed during pregnancy only when the indication for the proce‐
dure is clear and there are no less invasive or therapeutical diagnosis ways. In order to per‐
form this operation it is necessary the patient`s informed consent. It should be taken into
account that the procedure should be postponed until second trimester. The specific indica‐
tions for endoscopy during pregnancy, as ASGE recommends are the following:
• Significant or continued GI bleeding
• Severe or refractory nausea and vomiting or abdominal pain
• Dysphagia or odynophagia
• Strong suspicion of colon mass
• Severe diarrhea with negative evaluation
• Biliary pancreatitis, choledocholithiasis, or cholangitis
• Biliary or pancreatic ductal injury
Also, there are a few principles (ASGE) to respect:
• have a strong indication
• preferably perform endoscopy during the second trimester of pregnancy




• minimize procedure time
• position pregnant patients in left pelvic tilt or left lateral position to avoid vena cava or
aortic compression
• presence of fetal heart sounds should be confirmed before sedation is begun and after the
endoscopic procedure
• obstetric support should be available in the event of a pregnancy-related complication
• endoscopy is contraindicated in obstetric complications such as placental abruption, im‐
minent delivery, ruptured membranes, or eclampsia.
The decision of performing an endoscopy to a pregnant patient must be taken by a team:
obstetrician – endoscopist – anaesthesist, because there must be analyzed: the implications
for the fetus, for the mother, the emergency of the situation and the possibility of therapeuti‐
cal alternatives in order to solve the issue in safety conditions or postponement after labor
[7]. An obstetrician must be available during the procedure if there are complications related
to the pregnancy.
4. Fetal and maternal risks in endoscopic explorations
4.1. Endoscopic risks for the fetus
They can be: hypoxy given to oversedation, fetal hyperperfusion given to maternal position,
teratogenity given to the medicines administration, uterine trauma along with the impact on
the fetus through endoscopic trauma, preterm labor through uterine compression. That is
why it is advisable to avoid the performance of endoscopies in first trimester, excepting clin‐
ical emergency cases.
Among these risks, potential risk to dermine a malformation in fetal development through
pills administration, early labor or giving mechanical uterine trauma seriously need evalua‐
tion when it is being analyzed an endoscopic procedure to pregnant people. Moreover, med‐
ical and ethical problems require a reticence for doctors and pregnant people in what
concerns endoscopic studies and require the patient`s informed consent. Fetal normal status
must be confirmed before starting the endoscopy and it must be revaluated as soon as possi‐
ble after its completion.
There is no evidence that certifies increased fetal morbidity for pregnant women that are
subject to endoscopic procedures in comparison with pregnant women that had not been
subject at any investigations. On the contrary, a case control study that enclosed a number of
83 superior digestive endoscopies performed to pregnant women showed that there had not
been any preterm labors and any new born children of these women had not different Ap‐
gar scores to birth in comparison with those women that had not performed these kind of
investigations [4].
A survey performed by 300 specialist gastroenterologists doctors, which included informa‐
tion regarding 73 digestive superior endoscopies and 13 colonoscopies performed during
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the pregnancy, did not succeed to report any significant complication for those pregnancies
[8]. Just as well, a series of groups from 10 medical centers reported an experience of 48 flex‐
ible sigmoidoscopies and 8 colonoscopies performed during the pregnancy [9] and dit not
report any negative result that could affect the fetus and that could be assigned to those en‐
doscopic procedures.
From the point of view of gestation development, fetal complications are: fetal abnormali‐
ties, labor induction, preterm labor that could be determined by endoscopic procedures,
having the greatest risk to appear in the first trimester of pregnancy [10]. In general, the sec‐
ond trimester is considered to have the lowest risk for endoscopic interventions.
Even if the studies that had been performed did not seem to indicate a negative result for
the fetus and which could have been assigned directly to endoscopy, the procedure itself re‐
quires a great caution from the doctors. Endoscopy, which has a diagnostic or therapeutical
role must be taken into consideration only when, without its execution, the risks are higher.
General rules are to postpone the procedure until labor or at least after first trimester of
pregnancy. Pre-procedure training of the pregnant woman must include a special examina‐
tion from the obstetrician and his availability in care of eventual complications. There will
be monitored the fetal heart beats before starting the procedure that will be revaluated as
soon as possible after the completion.
The risk of fetal hypoxy can be reduced through minimum sedation of the pregnant woman.
The procedure is not performed with the mother in position of lying down, because the
pregnant uterus can compress the aorta and/inferior vena cava that causes maternal hypo‐
tension and therefore it could interfere with the placental perfusion. Therefore it is advisable
left lateral position. American Society for Gastrointestinal Endoscopy has recently published
the guidelines that must be fulfilled for the endoscopy to pregnant women, based on availa‐
ble data and the consent of specialist doctors [11].
Fetal monitoring is made through the hearts beats with the help of a monitor and it allows to
the doctor to detect any fatal suffering. This difficulty can be improved through the correc‐
tion of maternal hypoxy or hypotension.
In 2009 ASA and American College of obstetrics and gynecology (ACOG) issued a common
statement regarding the endoscopic interventions performed during pregnancy [12]. The
document contains the following mentions:
• endoscopist must obtain a pre-operative examination together with the obstetrician be‐
fore performing each endoscopic procedure. This must be achieved no matter the gesta‐
tion age of the fetus.
• when the fetus is pre-viable, Doppler detection of fetal heart beats immediately before
and after the procedure is enough.
• when the fetus is viable, continuous intra-operative monitoring of fetal heart beats and
the presence of a gynecology surgeon is ideal, if it appears an emergency labor.





4.2. Endoscopic risks for the pregnant woman
Endoscopic risks for the pregnant woman can be:
• precipitated aspiration through abdominal dystensia
• hypotension through the compression of inferior vena cava
• uterine trauma through the anatomic modification
Maternal hypotension appears through the compression of inferior vena cava and the reduc‐
tion of venous return. That is why there must be avoided the supine position during the
procedures.
Compression of abdominal organs by the pregnant uterus can modify the digestive lumen
and therefore the duration of endoscopy can be extended, and for the vizualization it is nec‐
essary a higher amount of air breathed, the endoscope can jump-up (especially to colonos‐
copies) and it can appear an abdominal dystensia accompanied by a discomfort of the
pregnant woman.
Endoscopy for pregnant women is made only in carefully selected cases. It can’t be made an
endoscopy in case of an imminent abortion or if there are some obstetrical problems. The
procedure is better performed during day in a specialized endoscopy office. It can be admin‐
istered oxygen, but it is not compulsory.
5. Sedative medication used for endoscopy in pregnancy
As well the mother and the fetus are subject to some potential risks in case of endoscopic
sedation. These risks vary according to pregnancy trimester.
Sedative and analgesic agents should always be used in that smaller dose in order to mini‐
mize the potential risk of teratogenic effects. The highest risk for the fetus takes place during
the first trimester when it is the most vulnerable to possible teratogenic effects.
As there are no well controlled studies regarding the safety of the fetus towards the pharma‐
cological agents that are used for sedation in the pregnant women endoscopy, no medicine
has been framed by FDA in class A, without teratogenity [13].
Data for safe medicines, not teratogenic, are reduced, because the clinical studies to preg‐
nant women are very rarely performed, they are expensive and require long term monitor‐
ing [14]. This point of view led to the recommendation of sedative medicines for endoscopy
during the pregnancy in very small quantities and only if it is strictly necessary.
A good cooperation between the pregnant woman and gastroenterologist should bring to
the performance of a fast endoscopic procedure, simple and without sedation. But most of
them are made in emergency situations and with therapeutical intentions. In these situations
it is necessary the sedation, and the endoscopist should consult with obstetrician doctor and
with anasthesist about the anesthesic medicines, taking into account the FDA classification
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of teratogenity of medicines. It is very important that the doctor be familiar with the stages
of fetal development and teratogenesis. At two weeks from the conception, embrionary cells
are subject to the law „all or nothing”. In this period the exposure to toxic drugs will lead
either to a normal and healthy fetus or the embryo will not be viable. In the next eight weeks
and until the second trimester it appears the difference of cells and organogenesis. At the
moment, the exposure to teratogenic medicines will have as a result severe congenital mal‐
formations. In the second and third trimester the medicines can still generate fetal toxicity,
especially from the neurological point of view.
In order to classify their safety when using in pregnancy, drugs were divided by FDA into 5
categories:
1. category A – defined as adequate and well controlled studied in pregnant women;
2. category B - animal studies have revealed no evidence of harm to the fetus, but there
are no adequate studies in pregnant women or animal studies have shown an adverse
effect, but adequate studies in humans have failed to demonstrate a risk to the fetus;
3. category C - animal studies have shown an adverse effect, and there are no adequate
studies in pregnant women or no animal studies have been conducted and there are no
adequate studies in pregnant women;
4. category D - studies in pregnant women have demonstrated a risk to the fetus (howev‐
er, the benefits of therapy may outweigh the risk);
5. category X - studies in both animals and humans have demonstrated evidence of fetal
abnormalities; use is contraindicated in women who are or may be pregnant.
Because there are no well controlled studies regarding fetus safety when using pregnant pa‐
tients sedation in endoscopy, no drug was classified as category A by the FDA.
Most of the drugs used in pregnant patients sedation are category B or C. Category D drugs
should be avoided and used only when the benefit outweighs the risks, while category X it
is not used at all. Sedation should be moderate or anxiolisis; in case of deep sedation is need‐
ed, it should be only under the surveillance of a specialised anesthesiologist. It should be
used the lowest efficacious dose of sedation or, if possible, the endoscopy should be per‐
formed without any sedation: most upper endoscopies and sigmoidoscopies can be accom‐
plished without sedation.
The  most  common  medicines  that  are  used  for  endoscopic  sedation  and  analgesia  are
Meperidine, Fentanyl, benzodiazepines and Propofol.  Meperidine (FDA category B) does
not seem to be teratogenic. It is better than choosing Fentanyl during pregnancy. Fentan‐
yl  (FDA  category  C)  as  well,  can  be  relatively  safe  in  small  doses,  but  there  are  few
available data referring to its safety. The use of some benzodiazepines (FDA category D)
is not yet controversial.
The use of Diazepam is not recommended during pregnancy. The use of Diazepam dur‐
ing pregnancy had been associated with split of the hard palate to new born infants, ac‐




these  results  [16].  Midazolam has  not  been  associated  with  fetal  malformations,  but  its
use must be avoided in the first  trimester.  The safety of Propofol (FDA category B) has
not yet been established, but taking into account the short duration of action, with mini‐
mum secondary  effects,  it  could  be  a  drug of  choice  when it  is  necessary  a  more  pro‐
found sedation.
In the first trimester endoscopic procedures must rather be achieved without sedation or by
using Meperidine all alone. In the second and third trimester Meperidine remains the first
choice drug, but little doses of Midazolam can be added according to needs.
If it is necessary a more profound sedation, it is recommended the examination with the an‐
aesthesist. The pregnancy in trimesters two and three represents a great challenge for endos‐
copies, taking into account the management of airways, sedation and monitoring cardiac
and respiratory functions and the fluids balance. Approaching must be made by a team that
includes the obstetrician, anaesthesist and the endoscopist working together in a hospital.
There are certain drugs commonly used in gastrointestinal endoscopy: meperidine, fentanyl,
naloxone, benzodiazepines, pethidine, flumazenil, propofol, simethicone, glucagon, topical
anesthetics, colon-cleansing agents that need to be discussed extensively, according to their
category.
5.1. Meperidine (category B)
Of all opioidagonists that have teratogenic effects on animals, meperidine appears to be safe
when being used for endoscopy in pregnant women[17; 18]. This is one of the standard
drugs used for analgesia and sedation and is the preferred opiate during pregnancy. It does
not cross the blood brain barriers or a pidasmorphineandis often used by obstetricians for
analgesia during labor. However, using high doses close to birth time, may cause neonatal
respiratory depression. Meperidine may also be responsible for transient fetal heart rate ab‐
normalities, but in the absence of other fetal changes it can not be considered an indicator of
poor prognosis in this situation[19].
To obtain the minimum sedation effect during endoscopy in pregnant women it should be
used the lowest dose, limited to a maximum of 75 mg meperidine during routine explora‐
tion. In case of occasional occurrence of respiratory depression or hypotension secondary to
opiate use, there can be used rapid acting opiate antagonists such as naloxone (B category)
[20]. It crosses the placenta shortly after administered to the mother and was not shown to
be associated with teratogenicity. It is preferred compared to fentanyl and morphine.
5.2. Fentanyl (category C)
It is considered that fentanyl is a safe opiate when used in low doses if administered during
pregnancy. It has a faster onset of action than meperidine and is generally indicated in preg‐
nant patients with a previous history of seizures. Although it was found as being embryoci‐
dal to rats, clinical experience in pregnant women was very similar to meperidine [21].
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5.3. Naloxone (category B)
It doesn’t seem to be teratogenic. It is contraindicatedin mothers who are dependent on opi‐
ates because it may precipitate opiate-withdrawal symptoms. It is being used only in cases
of respiratory depression, hypotension, or lack of response and under strict monitoring. It
should be noted that there is a risk of resedation due to metabolising the drug.
5.4. Flumazenil (category C)
It is a benzodiazepine antagonist, not very well studied, but it seems it might determine
neurobehavioral changes in rats if exposed to it in utero.
5.5. Benzodiazepines (category D)
Diazepam accumulates rapidly into fetal circulation after maternal administration and was
associated with congenital defects in mice. As concerning the occurrence of similar anoma‐
lies in humans, opinions are divided. The data suggest that administration of diazepam in
early pregnancy appears to be a risk factor, although using it during the second and third
trimester could theoretically determine neurobehavioral disorders in neonates [25]. There‐
fore, the conclusion is that diazepam should not be used during pregnancy.
Midazolam is the most commonly used sedative for endoscopic procedures. Although it
crosses the placentaandcanbedetected to the fetus, unlike diazepam, it is not concentrated in
the fetal circulation and was not associated with congenital defects. However, belonging to
benzodiazepines, it has the neonatal respiratory depressant potential. Therefore it should be
used in small doses, with great care under the supervision of ananesthesiologist, when seda‐
tion with meperidineisin sufficient [26].A meta-analysis of studies on the risks of anesthesia
for gastroscopies during pregnancy concluded that the only potential problem is a slight in‐
creased incidence of abortion in the first or second trimester of pregnancy[27]. It is not rec‐
ommended during the first trimester of pregnancy [28].
5.6. Propofol (category B)
Propofolis an increasingly used for endoscopy sedative drug, especially in the United States.
It is short acting, with a much shorter recovery period than other sedative pharmacological
agents[22]. However, following an arrow therapeutic index and potential respiratory de‐
pression, itis generally administered only by anesthesiologists. Gastroenterologists’ medical
societies have recommended that this agent should be reserved for deeper sedation and oth‐
er complicated clinical situations in a highly monitored for vital functions environment [23].
It is considered relatively safe for use during pregnancy, although few data are available re‐
garding its use in the first trimester of pregnancy[24].
5.7. Simethicone (category C)
It is frequently used in pregnant patients, with no reported addverse effects, but it is not ex‐




5.8. Glucagon (category B)
It is a safe to use antispasmodic, especially in ERCP.
5.9. Topical anesthetics (category B)
Lidocaine is used to provide pharingeal anesthesia and it was reported as being safe to use
even in the first trimester of pregnancy.
5.10. Colon cleansing-agents
Most of them are category C, due to lack of studies during pregnancy, and this is the case for
PEG solutions (polyethylene glycol) and sodium phosphate solutions which can cause fluid
disturbance. It is considered that for flexible sigmoidoscopy tap water enemas are sufficient.
6. Endoscopy and variceal bleeding in pregnancy
Variceal gastrointestinal bleedings during pregnancy are true emergencies. A delay in their
treatment could lead to serious complications and even death of the mother and fetus. Ther‐
apeutic endoscopic procedures (sclerotherapy) are recommended as first line treatment. Ef‐
fectiveness and relative safety of these approaches during pregnancy is documented in the
literature [29]. Octreotide is used to treat variceal bleeding but its safety in pregnancy has
not been established.Non-variceal gastrointestinal bleeding were successfully treated with
endoscopic therapy during pregnancy using an epinephrine injection plus either placement
of hemostatic clips or thermo-coagulation.
7. Endoscopic Retrograde Cholangiopancreatography (ERCP)
It is strongly recommended to be performed by very well trained endoscopists and is indi‐
cated in pregnant patients with pancreatitis, cholangitis, choledocholithiasis (complicated
with jaundice, impacted or not). If possible, ERCP should be postponed from the first tri‐
mester to the second in order to minimize irradiation’s potential teratogenic effect. There
should be used a lead shielding for the patient’s abdomen, a guidewire as opposed to injec‐
tion of contrast and minimal use of fluoroscopy and spot radiographs.
8. Lower endoscopy
It is indicated in important lower intestinal bleeding, severe unexplained diarrhea and colon
neoplasm suspicion. Colorectal cancer screening or change in bowel habits are indications
that may be postponed for the postpartum period.
Most of the studies specify sigmoidoscopy as a safely procedure during pregnancy (in sta‐
ble pregnant patients, having strong indication: sigmoid or rectal mass, severe diarrhea –
prolonged and not responding to specific treatment, lower intestinal hemorrhage). It should
be postponed until after birth for patients complaining abdominal pain or change in bowel
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habits. Sigmoidoscopy is not causing congenital abnormalities and isn’t inducing labor, all
studies performed so far reporting delivery of healthy new borns at term.
Colonoscopy safety during pregnancy is not yet properly studied, thus guidelines are not
available. It is recommended only for life-threatening situations. Maneuvers like placing the
patient in the prone position or exerting external abdominal compression should be avoid‐
ed, especially in the third trimester of pregnancy.
9. Nonendoscopic imaging modalities of the digestive tract during
pregnancy
There can be used endoscopic videocapsules which offer theoretical advantages of gastroin‐
testinal mucosa inspection. They do not need sedation of the patient or mechanical pressure
on the abdomen, but safety of their use during pregnancy is unknown. Originally designed
to view the small intestine, a change in the original design is now available to inspect the
esophagus. It remains to be seen if technical adjustments of this technology will allow future
use for the colonas well.
Virtual  colonoscopy by MRI is  safer  during pregnancy than using classic  CT.  Although
still classified as "experimental", virtual technologies are increasingly used as a screening
tool  for  colorectal  neoplasia.  However,  its  safety  has  not  been studied in  pregnancy al‐
though there are some reports showing the usefulness and lack of teratogenicity from ab‐
dominal  MRI  with  gadolinium  as  contrast  agent  in  different  clinical  situations  during
pregnancy [30; 31; 32].
10. Conclusions
Performing endoscopies in pregnant patients has not only to be done by a physician experi‐
enced in general gastroenterology and endoscopic procedures but also highly experienced
in performing such procedures in pregnant women. It is not recommended for these endos‐
copies to be performed by a beginner, as they carry the unique issue of fetal safety. Endo‐
scopic interventions in pregnancy must be performed quickly and with caution. The
endoscopist should always be prepared to discontinue the action at any time for safety rea‐
sons. An anesthesiologist and an obstetrician must be part of the working team, especially
ready for emergencies.
A number of studies concluded that esophagogastroduodenoscopy and sigmoidoscopy are
not contraindicated during pregnancy. If for instance significant upper gastrointestinal
bleeding is suspected, emergency esophagogastroduodenoscopy should be performed. Sig‐
moidoscopy is to be considered when the pregnant patient is stabilized, and only if strong




Even if no definitive data exist at the present time, ERCP should be performed when the
possibility for a sphincterotomy exists. It should only be attempted by highly trained per‐
sonnel, in a center with extensive experience and the resources to resolve all possible issues
that may incur.
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